Drugs / CD7.CAR/28zeta T Cells
CD7.CAR/28zeta T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07220993 | May 2026 → Dec 2028 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7.CAR/28zeta T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07220993 ↗ |
| Known as | CD7 CD28 chimeric receptor- T cells | “Earlier, the patients previous bone marrow transplant donor gave the investigator blood to make CD7 CD28 chimeric receptor- T cells in the laboratory.” NCT07220993 ↗ |
| Known as | CD7 chimeric receptor T cells with CD28 | “These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.” NCT07220993 ↗ |
| Known as | CD7 chimeric receptor-T cells | “These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.” NCT07220993 ↗ |
| Action | Deplete | “T cells can kill tumor cells” NCT07220993 ↗ |
| Modality | Cell therapy | “These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.” NCT07220993 ↗ |
| Route | Intravenous | “Patients will be given an injection of cells into the vein through an IV at the assigned dose.” NCT07220993 ↗ |